Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Omalizumab drug survival in chronic urticaria patients shows good long-term effectiveness, with well-controlled disease being the primary reason for stopping treatment. Predictors for discontinuation include fast response and disease duration.
Area Of Science
- Immunology
- Dermatology
- Pharmacology
Background
- Omalizumab is a safe and effective treatment for chronic urticaria (CU) in clinical trials.
- Real-world data on long-term omalizumab drug survival in CU patients are limited.
- Understanding reasons for discontinuation and predictors is crucial for treatment management.
Purpose Of The Study
- To evaluate omalizumab drug survival in a large, diverse population of CU patients.
- To identify reasons and predictors for omalizumab discontinuation in clinical practice.
Main Methods
- International multicenter cohort study at 14 Urticaria Centers of Reference and Excellence.
- Inclusion of all CU patients treated with omalizumab.
- Drug survival analysis using time to discontinuation and Cox regression for predictor identification.
Main Results
- 2325 CU patients included; mean age 42 years, 71% female.
- Median omalizumab survival time was 3.3 years; 39% survival at 7 years.
- Well-controlled disease was the main reason for discontinuation (65%), followed by ineffectiveness (18%) and adverse effects (4%).
- Fast treatment response predicted higher discontinuation due to well-controlled disease (HR 1.45).
- Longer disease duration (>2 years) predicted lower discontinuation due to well-controlled disease (HR 0.81).
- Immunosuppressive cotreatment and autoimmune disease increased discontinuation for ineffectiveness (HR 1.65).
- Spontaneous wheals (HR 0.62) and higher dosages (HR 0.40) decreased discontinuation for ineffectiveness.
Conclusions
- Omalizumab demonstrates effective and safe long-term use in real-world CU treatment.
- Well-controlled disease is the primary driver for omalizumab discontinuation.
- Findings can guide clinical decisions and expectation management for CU patients.
- Further research into biomarkers for complete remission in omalizumab responders is warranted.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
5-Lipoxygenase Inhibitors: Some drugs in this class, like zileuton (Zyflo), inhibit an enzyme called 5-lipoxygenase. This enzyme is crucial in synthesizing...
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...